Multimodal Therapy for Fatigue in Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical research study is to learn about the effect of different combinations of exercise, supportive counseling, and methylphenidate/placebo for the treatment of fatigue in patients with prostate cancer. The safety of this treatment combination will also be studied.Methylphenidate is a stimulant designed to increase the activity of the central nervous system.A placebo is not a drug. It looks like the study drug but is not designed to treat any symptom, disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.The exercise in this study is designed to help improve your physical fitness and energy levels.Supportive counseling is designed to help to control symptoms, fatigue, anxiety, depression, pain, and/or sleep disorders.
Will I have to stop taking my current medications?
You may need to stop taking certain medications, such as monoamine oxidase inhibitors, tricyclic antidepressants, clonidine, anticoagulants, anticonvulsants, and some tricyclic drugs, to participate in this trial. If you are currently taking methylphenidate, you must stop at least 10 days before joining the study.
Is methylphenidate safe for treating fatigue in cancer patients?
How does the drug methylphenidate differ from other treatments for fatigue in prostate cancer?
Methylphenidate is unique because it is a psychostimulant (a type of drug that increases activity in the brain) used to specifically target and reduce fatigue in cancer patients, including those with prostate cancer. Unlike other treatments, it can be patient-controlled, allowing individuals to manage their fatigue symptoms more directly.34678
What data supports the effectiveness of the drug methylphenidate for reducing fatigue in prostate cancer patients?
Research shows that methylphenidate can help reduce fatigue in cancer patients, including those with prostate cancer, as it has been found to improve fatigue symptoms in several studies. For example, a study found that methylphenidate significantly improved fatigue symptoms in patients with chemotherapy-related fatigue.13469
Who Is on the Research Team?
Sriram Yennurajalingam, MD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with prostate cancer experiencing daily fatigue, who are about to start radiotherapy with androgen deprivation therapy. They must not be heavily active or using certain therapies or medications that could interfere with the study, have a reasonable level of physical function (Zubrod status 0-2), and no severe cognitive issues or cardiac disease.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants complete a baseline exercise assessment including sit-to-stand test, hand-grip strength test, and 6-minute walk test
Treatment
Participants receive methylphenidate/placebo, engage in exercise, and participate in cognitive therapy or supportive counseling
Follow-up
Participants are monitored for safety and effectiveness after treatment, including physical exams and performance tests
What Are the Treatments Tested in This Trial?
Interventions
- Cognitive Behavioral Therapy (CBT)
- Counseling Sessions
- Methylphenidate
- Placebo
- Sham Exercise
- Standardized Exercise Intervention Program
Methylphenidate is already approved in United States, Canada, European Union for the following indications:
- Attention Deficit Hyperactivity Disorder (ADHD)
- Narcolepsy
- Attention Deficit Hyperactivity Disorder (ADHD)
- Narcolepsy
- Attention Deficit Hyperactivity Disorder (ADHD)
- Narcolepsy
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
American Cancer Society, Inc.
Collaborator